FENC Projected Dividend Yield

Fennec Pharmaceuticals Inc ( NASDAQ : FENC )

Fennec Pharmaceuticals is a biopharmaceutical company focused on its product candidate, PEDMARK® (sodium thiosulfate injection), which is used to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Co. has established Fennec HEARS™, a single source program designed to connect PEDMARK® patients to both patient financial and product access support. The program provides assistance and resources, regardless of insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met.

20 YEAR PERFORMANCE RESULTS